Rivaroxaban is used to treat or prevent blood clots (venous thromboembolism, or VTE). Blood clots can occur in the legs (deep vein thrombosis, DVT) or the lungs (pulmonary embolism, PE).

2025年1月7日 · varoxa is a highly selective direct factor Xa inhibitor. Inhibition of factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibits thrombin formation. varoxa does not inhibit thrombin (activated factor II) and no effects on platelets have been demonstrated.

2021年4月27日 · Rivaroxaban oral tablet is used to treat and prevent blood clots. It’s also used to reduce the risk of stroke in people with atrial fibrillation without an artificial heart valve. In...

Rivaroxaban, sold under the brand name Xarelto among others, is an anticoagulant medication (blood thinner) used to treat and prevent blood clots. [10] . Specifically it is used to treat deep vein thrombosis and pulmonary emboli and prevent blood clots in atrial fibrillation and following hip or knee surgery. [10] . It is taken by mouth. [10]

2023年4月7日 · Limited data are available on the relative efficacy of this drug and warfarin in reducing risk of stroke and systemic embolism when warfarin therapy is well-controlled. 15 mg orally twice a day. This dosage should be taken with food, at the same time each day. 15 mg orally twice a day.

To treat blood clots in the veins of your legs and blood clots in the blood vessels of your lungs, and for preventing blood clots from re-occurring. The recommended dose is one tablet Rivaroxaban 15 mg twice a day for the first 3 weeks. For treatment after 3 weeks, the recommended dose is one tablet Rivaroxaban 20 mg once a day.

Rivaroxaban belongs to the family of medications called anticoagulants. Anticoagulants prevent harmful blood clots from forming in the blood vessels by reducing the ability of the blood to clot. Rivaroxaban is used to prevent blood clots for people who have had total hip replacement or knee replacement surgery.

ريفاروكسابان (بالإنجليزية: Rivaroxaban) ، هو من مضادات التخثر الفموية غير المعتمدة على فيتامين ك (Non-vitamin K antagonist oral anticoagulants)، ويمنع تنشيط الصفائح الدموية وبالتالي يمنع تكوّن الجلطات من خلال تثبيط عامل التخثر Xa.

2020年2月17日 · Inhibits platelet activation and fibrin clot formation via direct, selective and reversible inhibition of factor Xa (FXa) in both the intrinsic and extrinsic coagulation pathways. FXa, as part of the prothrombinase complex consisting also of factor Va, calcium ions, factor II and phospholipid, catalyzes the conversion of prothrombin to thrombin.

The drug VAROXA contains one active pharmaceutical ingredient (API): 1 Rivaroxaban UNII 9NDF7JZ4M3 - RIVAROXABAN. Rivaroxaban is a highly selective direct factor Xa inhibitor with oral bioavailability. Inhibition of factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibiting both thrombin formation and ...